Vimarsana
Biggest News Aggregation in the World

Page 4 - Acticor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acticor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acticor Today - Breaking & Trending Today

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2022 - Vimarsana News

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2022

Published: June 7, 2022

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralNewton BiocapitalVenture InvestmentInternational Investors KaristaFrench National Institute Of HealthRegulation Of The French Financial Markets AuthorityRegulatory NewsFrench Commercial CodeGeneral RegulationFrench Financial Markets AuthorityEuronext Growth ParisFrench National InstituteMedical ResearchInternational InvestorsActicor Biotech
ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022 - Vimarsana News

ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022

Published: May 9, 2022

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies,announces today the

Source: finanznachrichten.de
Related Topics:
Newton BiocapitalMikael MazighiVenture InvestmentEuropean Stroke Organisation ConferenceFrench National Institute Of HealthEuropean Stroke OrganisationRegulatory NewsFriday MayProfessor Mikael MazighiCoordinating InvestigatorCeremony Large Clinical TrialsNovel AntithromboticReduced Intracranial HemorrhageMortality RatesStandard Of Care Reperfusion TherapiesFrench National InstituteMedical ResearchMirae Asset CapitalPrimer CapitalActicor BiotechEuronext Growth ParisStroke Journal
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2022 - Vimarsana News

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2022

Published: May 4, 2022

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralNewton BiocapitalVenture InvestmentInternational Investors KaristaFrench National Institute Of HealthRegulation Of The French Financial Markets AuthorityRegulatory NewsFrench Commercial CodeGeneral RegulationFrench Financial Markets AuthorityEuronext Growth ParisFrench National InstituteMedical ResearchInternational InvestorsActicor Biotech
ACTICOR BIOTECH: Availability of the 2021 Universal Registration Document and the Preparatory Documents for the Combined General Meeting of May 12, 2022 - Vimarsana News

ACTICOR BIOTECH: Availability of the 2021 Universal Registration Document and the Preparatory Documents for the Combined General Meeting of May 12, 2022

Published: April 27, 2022

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announces

Source: finanznachrichten.de
Related Topics:
France GeneralFaubourg Saint JacquesNewton BiocapitalVenture InvestmentFrench National Institute Of HealthRegulatory NewsUniversal Registration DocumentCombined General MeetingDes MarchEntreprises Paris CochinActicor BiotechBulletin Des AnnoncesGeneral MeetingVaccine PassFrench CommercialFrench Commercial CodeFrench National InstituteMedical ResearchMirae Asset CapitalPrimer CapitalEuronext Growth Paris
ACTICOR BIOTECH: Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development - Vimarsana News

ACTICOR BIOTECH: Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development

Published: March 30, 2022

Successful IPO on Euronext Growth in Paris Cash position of €11.3 million at 31 December 2021 Promising clinical results with the continuing development of glenzocimab for use in stroke Regulatory

Source: finanznachrichten.de
Related Topics:
United StatesFrance GeneralNewton BiocapitalGilles AvenardCorinne Le GoffNet ResearchGiven The CompanyVenture InvestmentFrench National Institute Of HealthFrench Financial Market Authority OnDrug AdministrationEuronext GrowthChief Executive OfficerActicor BiotechInvestigational New DrugAcute Ischemic StrokeAssistance Publique HFrench National InstituteMedical ResearchMirae Asset CapitalPrimer CapitalEuronext Growth ParisFinancial Market AuthorityStatutory Auditors